Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/309% above fair value
$80.28+3.39 (+4.41%)
Close on Nov 13, 2026Market cap $3.52BP/E –Yield 0.00%
Tarsus Pharmaceuticals statistics
86 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Feb 22, 2027 (estimated, after the close)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Jun 30, 2026
- Share price as of
- Nov 13, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 10.37
- 2.22
- P/OCF Ratio
- 47.51
- 12.99
Enterprise valuationIndustry
- EV / Sales
- 5.19
- 2.57
- EV / FCF
- 56.18
- 22.27
Share statisticsIndustry
- Shares Change (YoY)
- 8.24%
- 10.8%
- Shares Change (QoQ)
- 0.58%
- 0.50%
- Float
- 43M
- 49M
- Shares Held by Insiders
- 3.13%
- 11.7%
- Shares Held by Institutions
- 110.0%
- 56.4%
Short sellingIndustry
- Short Interest
- 6M
- –
- Short Interest Change
- 5.85%
- -0.80%
- Short % of Float
- 14.3%
- 9.01%
- Short % of Shares Outstanding
- 13.8%
- 6.30%
- Days to Cover
- 6.94
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $91.53
- –
- 52-Week Low
- $53.89
- –
- 20-Day Moving Average
- $72.15
- –
- 50-Day Moving Average
- $74.85
- –
- 200-Day Moving Average
- $67.97
- –
- Average True Range (14)
- $3.82
- –
- Price Change (1 Week)
- 17.0%
- -1.15%
- Price Change (1 Month)
- 13.1%
- -4.87%
- Price Change (3 Months)
- 13.7%
- -21.0%
- Price Change (6 Months)
- 28.5%
- -20.6%
- Price Change (YTD)
- -1.95%
- -23.6%
- Price Change (1 Year)
- 7.31%
- -22.4%
- Price Change (3 Years)
- 348.0%
- -29.5%
- Price Change (5 Years)
- 195.3%
- -77.9%
- Average Volume (10 Days)
- 1M
- –
- Average Volume (20 Days)
- 861,583
- –
- Average Volume (90 Days)
- 910,730
- –
- Relative Volume
- 0.79
- 0.70
- Relative Strength Index (14)
- 64.8
- 43.4
- Volatility (1 Year)
- 45.0%
- 80.1%
- Beta (5 Years)
- 0.66
- 1.07
MarginsIndustry
- EBITDA Margin
- -8.00%
- -27.7%
- FCF Margin
- 9.24%
- -9.56%
Returns on capitalIndustry
- Return on Equity (ROE)
- -13.7%
- -49.9%
- Return on Assets (ROA)
- -8.40%
- -40.6%
- Return on Capital Employed (ROCE)
- -11.1%
- -37.9%
Financial positionIndustry
- Current Ratio
- 3.20
- 3.30
- Quick Ratio
- 3.11
- 2.39
- Debt / Equity
- 0.21
- 0.49
- Debt / FCF
- 1.30
- 4.65
- Interest Coverage
- -5.54
- -6.35
GrowthIndustry
- Revenue Growth (YoY)
- 105.2%
- 6.82%
- Revenue Growth (3Y CAGR)
- 159.5%
- 2.25%
EfficiencyIndustry
- Asset Turnover
- 1.10
- 0.40
- Revenue Per Employee
- $1.64M
- $429.29K
- Profits Per Employee
- -$125.61K
- -$689.41K
- Employee Count
- 370
- 74
- WACC
- 8.40%
- 10.2%
Income statement (TTM)Industry
Balance sheetIndustry
- Net Cash (Debt)
- $376.93M
- $17.76M
- Net Cash Per Share
- $8.59
- $0.80
- Equity (Book Value)
- $346.73M
- $53.89M
- Book Value Per Share
- $7.90
- $1.50
- Tangible Book Value
- $339.85M
- $27.13M
- Working Capital
- $386.24M
- $79.99M
Cash flow (TTM)Industry
- Capital Expenditures
- -$18.16M
- -$1.00M
- FCF Per Share
- $1.28
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- -1.32%
- -21.8%
- FCF Yield
- 1.59%
- -9.44%
- Dividend Yield
- 0.00%
- 1.88%
- Shareholder Yield
- 0.00%
- 0.00%
- Dividend Per Share
- $0.00
- $0.83
- Years of Dividend Growth
- 0
- 0
Taxes and interestIndustry
- Interest Expense
- $8.77M
- $2.90M
Scores and fair valueIndustry
- Altman Z-Score
- 8.45
- 0.23
- Piotroski F-Score
- 4
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | TARS | S&P 500 | Difference | TARS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +13.4% | -3.0% | +16.4 pts | ||
| 3 months | +16.6% | -2.8% | +19.3 pts | ||
| Year to date | -2.0% | +11.5% | −13.4 pts | ||
| 1 year | +10.7% | +13.5% | −2.8 pts | ||
| 3 years | +367.6% | +77.7% | +289.9 pts | +67.2% | +21.1% |
| 5 years | +195.3% | +72.6% | +122.6 pts | +24.2% | +11.5% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
6M TARS shares were sold short on Oct 30, 2026, up 5.8% from the previous report, or 14.27% of the shares available to trade. At recent volumes it would take 6.9 days to buy them back. Over the last 20 sessions, 70.7% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 6,066,524 | +5.8% | 874,486 | 6.9 |
| Oct 15, 2026 | 5,731,409 | -5.6% | 1,004,501 | 5.7 |
| Sep 30, 2026 | 6,070,928 | -0.9% | 732,012 | 8.3 |
| Sep 15, 2026 | 6,127,884 | +1.9% | 923,426 | 6.6 |
| Aug 31, 2026 | 6,011,550 | +0.2% | 613,155 | 9.8 |
| Aug 14, 2026 | 5,997,475 | -0.3% | 801,093 | 7.5 |
| Jul 31, 2026 | 6,016,830 | +4.0% | 914,420 | 6.6 |
| Jul 15, 2026 | 5,783,063 | -1.8% | 1,819,244 | 3.2 |
| Jun 30, 2026 | 5,889,643 | +18.3% | 943,186 | 6.2 |
| Jun 15, 2026 | 4,979,585 | -2.9% | 559,334 | 8.9 |
| May 29, 2026 | 5,125,873 | +4.5% | 690,081 | 7.4 |
| May 15, 2026 | 4,905,282 | +1.8% | 855,835 | 5.7 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?